PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression, is pleased to announce the addition of Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors.
PITTSBURGH, June 14, 2023 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression, is pleased to announce the addition of Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors.
"We are thrilled and privileged to welcome Dr. Marks as a distinguished member of PredxBio's board of directors," expressed Dusty Majumdar, PhD, CEO of PredxBio. "As a highly regarded pioneer in the field of oncology with extensive experience and a demonstrated history of visionary leadership in cancer care, Dr. Marks brings invaluable insights that will greatly contribute to our ongoing advancements at PredxBio."
Dr. Stanley Marks, MD, holds the prestigious position of Chairman of UPMC Hillman Cancer Center, serving as the Chief of the Division of Hematology-Oncology at UPMC Shadyside, and a Clinical Professor of Medicine at the University of Pittsburgh. Dr. Marks was also honored by UPMC and his medical partners at Oncology Hematology Association (OHA) through the establishment of the Stanley M. Marks – OHA Endowed Chair in Hematology/Oncology Leadership. With a remarkable career in cancer research, Dr. Marks has held key leadership roles such as President of The Leukemia & Lymphoma Society and has been a member of the board of directors of the American Cancer Society, among others. Recognized as one of the "Best Cancer Doctors in America," Dr. Marks is a highly respected clinician and a passionate advocate for patients. His impact is evident through the establishment of the Dr. Stanley Marks Research Endowed fund at the Hillman Cancer Center, which has raised an impressive $18 million for cancer research to date.
"I am excited to become a member of the board of directors at PredxBio, a company with immense potential to revolutionize biomarker discovery and clinical research through its advanced spatial biology analytics," commented Dr. Marks. "PredxBio's cutting-edge solutions offer scientists in the biopharma and health systems the ability to gain comprehensive and deep insights into the organization and interactions of cells within the tissue microenvironment. PredxBio's promising results in understanding of disease progression and treatment response to immunotherapy demonstrate the transformative power of this technology."
Welcoming Dr. Marks to PredxBio's board of directors, D. Lansing Taylor, PhD, Chairman of the Board at PredxBio and Director at the University of Pittsburgh Drug Discovery Institute (UPDDI), remarked, "Dr. Mark's deep experience in oncology and his leadership will be invaluable to PredxBio as we grow our business and pursue our mission to leverage the power of spatial biology with Explainable AI and unbiased spatial analytics in delivering innovative therapies that will positively impact the lives of patients."
The PredxBio platform seamlessly integrates multimodal data, such as spatial proteomics, spatial transcriptomics, and brightfield pathology, to uncover the hidden circuitries of tumor microenvironments and reveal the complex network biology of cancer. By performing highly scalable, Explainable AI (xAI) powered spatial analyses of diverse imaging techniques, PredxBio generates actionable insights for biomarker discovery, identifying drug targets, and designing effective clinical trials. Through the quantification of cell-cell interactions, identification of intermediate cell types and states, and discovery of microdomains, PredxBio delves into the organizing principles of spatial intratumor heterogeneity, providing a mechanistic understanding of tumor initiation, progression, and response to therapy. This comprehensive platform drives personalized therapeutic options, improving prediction accuracies based on spatial tumor biology and enabling optimal treatment selection for individual patients. With the launch of the PredxBio platform, we established our leadership position in Spatial Biology, uniquely capable of predicting patient outcomes with 90%+ accuracy by unraveling the hidden biological circuitries of cancer.
PredxBio is a Pittsburgh, PA-based company focused on the development of explainable AI-powered spatial analytics software platforms to decipher the complex cancer biology and bend the survival curve for immunotherapy cancer patients. PredxBio's solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. PredxBio has already completed engagements with early paying customers including pharma partners who are harnessing PredxBio's solutions to assess treatment response in immunotherapy.
S. Chakra Chennubhotla, PredxBio, Inc., 1 4122123115, [email protected]
SOURCE PredxBio, Inc.